$AXON
AXON ENTERPRISE, INC.

2021 Q1 Form 10-Q Financial Statement

#000155837021006312 Filed on May 07, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $195.0M $147.2M
YoY Change 32.52% 27.07%
Cost Of Revenue $71.67M $58.55M
YoY Change 22.39% 24.87%
Gross Profit $123.4M $88.61M
YoY Change 39.21% 28.57%
Gross Profit Margin 63.25% 60.21%
Selling, General & Admin $126.6M $63.03M
YoY Change 100.86% 46.94%
% of Gross Profit 102.63% 71.13%
Research & Development $47.02M $26.38M
YoY Change 78.23% 12.96%
% of Gross Profit 38.12% 29.77%
Depreciation & Amortization $4.291M $2.881M
YoY Change 48.94% 2.89%
% of Gross Profit 3.48% 3.25%
Operating Expenses $173.6M $89.41M
YoY Change 94.18% 34.96%
Operating Profit -$50.26M -$800.0K
YoY Change 6182.75% -129.95%
Interest Expense $585.0K $941.0K
YoY Change -37.83% -59.32%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$49.68M $141.0K
YoY Change -35331.91% -97.17%
Income Tax -$1.760M -$3.933M
% Of Pretax Income -2789.36%
Net Earnings -$47.92M $4.074M
YoY Change -1276.17% -36.53%
Net Earnings / Revenue -24.57% 2.77%
Basic Earnings Per Share -$0.75 $0.07
Diluted Earnings Per Share -$0.75 $0.07
COMMON SHARES
Basic Shares Outstanding 64.04M 59.61M
Diluted Shares Outstanding 64.04M 60.39M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $595.7M $345.2M
YoY Change 72.57% 4.92%
Cash & Equivalents $154.8M $156.5M
Short-Term Investments $440.8M $188.7M
Other Short-Term Assets $43.10M $34.70M
YoY Change 24.21% 4.2%
Inventory $89.66M $46.92M
Prepaid Expenses
Receivables $257.8M $191.9M
Other Receivables $0.00 $0.00
Total Short-Term Assets $986.2M $618.7M
YoY Change 59.39% 9.14%
LONG-TERM ASSETS
Property, Plant & Equipment $112.1M $43.07M
YoY Change 160.35% 4.16%
Goodwill $25.19M $24.75M
YoY Change 1.79% -1.06%
Intangibles $8.642M $11.93M
YoY Change -27.55% -20.83%
Long-Term Investments $78.50M $50.20M
YoY Change 56.37%
Other Assets $102.9M $59.46M
YoY Change 73.1% 67.57%
Total Long-Term Assets $418.6M $258.7M
YoY Change 61.81% 56.7%
TOTAL ASSETS
Total Short-Term Assets $986.2M $618.7M
Total Long-Term Assets $418.6M $258.7M
Total Assets $1.405B $877.5M
YoY Change 60.11% 19.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.79M $31.57M
YoY Change -37.31% 220.0%
Accrued Expenses $41.10M $36.40M
YoY Change 12.89% -8.89%
Deferred Revenue $165.1M $119.8M
YoY Change 37.77% 8.87%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $239.8M $195.0M
YoY Change 22.95% 15.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $27.87M $23.02M
YoY Change 21.08% -75.75%
Total Long-Term Liabilities $27.87M $23.02M
YoY Change 21.08% -75.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $239.8M $195.0M
Total Long-Term Liabilities $27.87M $23.02M
Total Liabilities $394.0M $317.9M
YoY Change 23.94% 20.08%
SHAREHOLDERS EQUITY
Retained Earnings $122.0M $175.7M
YoY Change -30.57% -1.18%
Common Stock $1.045B $543.3M
YoY Change 92.29% 18.07%
Preferred Stock
YoY Change
Treasury Stock (at cost) $155.9M $155.9M
YoY Change 0.0% 0.0%
Treasury Stock Shares $20.22M $20.22M
Shareholders Equity $1.011B $559.6M
YoY Change
Total Liabilities & Shareholders Equity $1.405B $877.5M
YoY Change 60.11% 19.87%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$47.92M $4.074M
YoY Change -1276.17% -36.53%
Depreciation, Depletion And Amortization $4.291M $2.881M
YoY Change 48.94% 2.89%
Cash From Operating Activities $60.94M $13.42M
YoY Change 354.26% -196.03%
INVESTING ACTIVITIES
Capital Expenditures $10.52M $2.209M
YoY Change 376.28% -58.09%
Acquisitions
YoY Change
Other Investing Activities -$43.56M -$19.82M
YoY Change 119.78% -81.18%
Cash From Investing Activities -$54.12M -$22.07M
YoY Change 145.2% -80.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -7.045M -5.162M
YoY Change 36.48% 345.38%
NET CHANGE
Cash From Operating Activities 60.94M 13.42M
Cash From Investing Activities -54.12M -22.07M
Cash From Financing Activities -7.045M -5.162M
Net Change In Cash -621.0K -15.71M
YoY Change -96.05% -87.51%
FREE CASH FLOW
Cash From Operating Activities $60.94M $13.42M
Capital Expenditures $10.52M $2.209M
Free Cash Flow $50.42M $11.21M
YoY Change 349.92% -158.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001069183
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Axon Enterprise, Inc.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-0741227
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
17800 North 85th Street
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
85255
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Scottsdale
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
AZ
CY2021Q1 dei City Area Code
CityAreaCode
480
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64673091
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63766555
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-16391
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
991-0797
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.00001 Par Value
CY2021Q1 dei Trading Symbol
TradingSymbol
AXON
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
64684364
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154822000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
155440000
CY2021Q1 us-gaap Short Term Investments
ShortTermInvestments
440842000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
406525000
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1796000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2105000
CY2021Q1 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
185373000
CY2020Q4 us-gaap Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
229201000
CY2021Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
72472000
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
63945000
CY2021Q1 us-gaap Inventory Net
InventoryNet
89657000
CY2020Q4 us-gaap Inventory Net
InventoryNet
89958000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
43063000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
36883000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
986229000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
981952000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
112119000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
105494000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
46403000
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
45770000
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8642000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9448000
CY2021Q1 us-gaap Goodwill
Goodwill
25194000
CY2020Q4 us-gaap Goodwill
Goodwill
25205000
CY2021Q1 us-gaap Long Term Investments
LongTermInvestments
78464000
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
90681000
CY2021Q1 us-gaap Long Term Accounts Notes And Loans Receivable Net Noncurrent
LongTermAccountsNotesAndLoansReceivableNetNoncurrent
18546000
CY2020Q4 us-gaap Long Term Accounts Notes And Loans Receivable Net Noncurrent
LongTermAccountsNotesAndLoansReceivableNetNoncurrent
22457000
CY2021Q1 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
26341000
CY2020Q4 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
20099000
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
102920000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
79917000
CY2021Q1 us-gaap Assets
Assets
1404858000
CY2020Q4 us-gaap Assets
Assets
1381023000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
19791000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
24142000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
41097000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
59843000
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5667000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5431000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
239775000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
256331000
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
116107000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
111222000
CY2021Q1 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
4697000
CY2020Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
4503000
CY2021Q1 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
4825000
CY2020Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
4732000
CY2021Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
684000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
649000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
27866000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
27331000
CY2021Q1 us-gaap Liabilities
Liabilities
393954000
CY2020Q4 us-gaap Liabilities
Liabilities
404768000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64673091
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63766555
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1044724000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
121984000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
169901000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
142000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
141000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1010904000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
962159000
CY2021Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
20220227
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
20220227
CY2021Q1 us-gaap Treasury Stock Value
TreasuryStockValue
155947000
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
155947000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
976255000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1404858000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1381023000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
195019000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
147162000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
71666000
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
58554000
CY2021Q1 us-gaap Gross Profit
GrossProfit
123353000
CY2020Q1 us-gaap Gross Profit
GrossProfit
88608000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
126597000
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
63027000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47018000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26381000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
173615000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
89408000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-50262000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-800000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
585000
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
941000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-49677000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
141000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1760000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3933000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-47917000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
4074000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64036000
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59609000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64036000
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60394000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-47917000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
4074000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2372000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47916000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2209000
CY2020Q1 axon Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
-2277000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-18062000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3562000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
6219000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4499000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
60939000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
13415000
CY2021Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
155825000
CY2021Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
10000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1702000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
976255000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-7045000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
89610000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-47917000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1010904000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
543495000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-5162000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20195000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
4074000
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2372000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
559590000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-47917000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
4074000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4291000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2881000
CY2021Q1 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-11000
CY2020Q1 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-13000
CY2021Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-45000
CY2020Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-517000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
89610000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
20195000
CY2021Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-598000
CY2020Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1548000
CY2021Q1 axon Provision For Unrecognized Tax Benefits
ProvisionForUnrecognizedTaxBenefits
194000
CY2020Q1 axon Provision For Unrecognized Tax Benefits
ProvisionForUnrecognizedTaxBenefits
341000
CY2021Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
2615000
CY2020Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
1156000
CY2021Q1 axon Credit Loss Reserve
CreditLossReserve
-335000
CY2020Q1 axon Credit Loss Reserve
CreditLossReserve
902000
CY2021Q1 us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
-31298000
CY2020Q1 us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
9700000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-520000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8630000
CY2021Q1 axon Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
6952000
CY2020Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
99512000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
132254000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
84315000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10521000
CY2020Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
78000
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
41000
CY2020Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
45000
CY2021Q1 axon Payments To Acquire Equity Securities Without Readily Determinable Fair Value
PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue
20000000
CY2020Q1 axon Payments To Acquire Equity Securities Without Readily Determinable Fair Value
PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue
4700000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-54123000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22073000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
28000
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
7045000
CY2020Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
5190000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7045000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5162000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-392000
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1890000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-621000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15710000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
155551000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
172355000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154930000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
156645000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154822000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
156540000
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
108000
CY2020Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
105000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154930000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
156645000
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4152000
CY2020Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3863000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
517000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
617000
CY2021Q1 us-gaap Investment Related Liabilities
InvestmentRelatedLiabilities
0
CY2020Q1 us-gaap Investment Related Liabilities
InvestmentRelatedLiabilities
13451000
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2021Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-47917000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
4074000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64036000
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59609000
CY2020Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
785000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64036000
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60394000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12234000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12161000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2021Q1 axon Warranty Period After Purchase Of Product
WarrantyPeriodAfterPurchaseOfProduct
P1Y
CY2020Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
769000
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1476000
CY2021Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
231000
CY2020Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
171000
CY2021Q1 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
406000
CY2020Q1 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
-85000
CY2021Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
944000
CY2020Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1220000
CY2021Q1 us-gaap Cash Surrender Value Fair Value Disclosure
CashSurrenderValueFairValueDisclosure
4800000
CY2020Q4 us-gaap Cash Surrender Value Fair Value Disclosure
CashSurrenderValueFairValueDisclosure
4700000
CY2021Q1 us-gaap Reclassifications
Reclassifications
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reclassification of Prior Year Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications are not material and had no effect on the reported results of operations.</p>
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
195019000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
147162000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
195019000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
147162000
CY2021Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
98813000
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
281193000
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
63871000
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
165086000
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
116107000
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
281193000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
163959000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
111222000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
275181000
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
165086000
CY2021Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
116107000
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
281193000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
163959000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
111222000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
275181000
CY2021Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1790000000
CY2021Q1 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
674265000
CY2021Q1 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
266000
CY2021Q1 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
111000
CY2021Q1 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
674420000
CY2021Q1 axon Cash Cash Equivalent And Investments Amortized Cost
CashCashEquivalentAndInvestmentsAmortizedCost
154824000
CY2021Q1 axon Short Term Investment
ShortTermInvestment
440957000
CY2021Q1 axon Long Term Investment
LongTermInvestment
78484000
CY2021Q1 us-gaap Debt Securities Held To Maturity Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAllowanceForCreditLoss
100000
CY2020Q4 us-gaap Debt Securities Held To Maturity Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAllowanceForCreditLoss
100000
CY2020Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
652816000
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
401000
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
128000
CY2020Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
653089000
CY2020Q4 axon Cash Cash Equivalent And Investments Amortized Cost
CashCashEquivalentAndInvestmentsAmortizedCost
155443000
CY2020Q4 axon Short Term Investment
ShortTermInvestment
406667000
CY2020Q4 axon Long Term Investment
LongTermInvestment
90706000
CY2021Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
45700000
CY2021Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
33918000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
39194000
CY2021Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
55739000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
50764000
CY2021Q1 us-gaap Inventory Net
InventoryNet
89657000
CY2020Q4 us-gaap Inventory Net
InventoryNet
89958000
CY2021Q1 us-gaap Cash Surrender Value Fair Value Disclosure
CashSurrenderValueFairValueDisclosure
4806000
CY2020Q4 us-gaap Cash Surrender Value Fair Value Disclosure
CashSurrenderValueFairValueDisclosure
4654000
CY2021Q1 us-gaap Capitalized Contract Cost Net Noncurrent
CapitalizedContractCostNetNoncurrent
32337000
CY2020Q4 us-gaap Capitalized Contract Cost Net Noncurrent
CapitalizedContractCostNetNoncurrent
32455000
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
59000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
62000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23168000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22308000
CY2021Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
29500000
CY2020Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
9500000
CY2021Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2211000
CY2020Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2211000
CY2021Q1 axon Prepaid Expenses Depositsand Other Assets Noncurrent
PrepaidExpensesDepositsandOtherAssetsNoncurrent
10839000
CY2020Q4 axon Prepaid Expenses Depositsand Other Assets Noncurrent
PrepaidExpensesDepositsandOtherAssetsNoncurrent
8727000
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
102920000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
79917000
CY2021Q1 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
0
CY2021Q1 axon Equity Securities Without Readily Determinable Fair Value Cost Basis Increase
EquitySecuritiesWithoutReadilyDeterminableFairValueCostBasisIncrease
2400000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
41097000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21880000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
36892000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1318000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9777000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10682000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3055000
CY2021Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
944000
CY2020Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
769000
CY2021Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
2482000
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
3848000
CY2021Q1 axon Accrued Inventory In Transit Current
AccruedInventoryInTransitCurrent
4696000
CY2020Q4 axon Accrued Inventory In Transit Current
AccruedInventoryInTransitCurrent
4597000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
59843000
CY2020Q4 axon Allowance For Expected Credit Losses On Customer Receivables
AllowanceForExpectedCreditLossesOnCustomerReceivables
3376000
CY2021Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
7200000
CY2021Q1 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2700000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3376000
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-304000
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
39000
CY2021Q1 axon Allowance For Doubtful Accounts Receivable Other
AllowanceForDoubtfulAccountsReceivableOther
135000
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3168000
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1796000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2105000
CY2021Q1 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
991000
CY2020Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
794000
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Noncurrent
AllowanceForDoubtfulAccountsReceivableNoncurrent
381000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Noncurrent
AllowanceForDoubtfulAccountsReceivableNoncurrent
477000
CY2021Q1 axon Allowance For Expected Credit Losses On Customer Receivables
AllowanceForExpectedCreditLossesOnCustomerReceivables
3168000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5800000
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.035
CY2021Q1 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies
EffectiveIncomeTaxRateReconciliationTaxContingencies
-0.205
CY2018Q2 axon Market Capitalization Goalfor Tranche First Tranche
MarketCapitalizationGoalforTrancheFirstTranche
2500000000
CY2018Q2 axon Market Capitalization Goalfor Tranche Incremental Increase
MarketCapitalizationGoalforTrancheIncrementalIncrease
1000000000.0
CY2021Q1 axon Revenue Goal Goal Number One
RevenueGoalGoalNumberOne
710058000
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Nine
AdjustedEBITDAGoalGoalNumberNine
125000000
CY2021Q1 axon Revenue Goal Goal Number Two
RevenueGoalGoalNumberTwo
860058000
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Ten
AdjustedEBITDAGoalGoalNumberTen
155000000
CY2021Q1 axon Revenue Goal Goal Number Three
RevenueGoalGoalNumberThree
1010058000
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Eleven
AdjustedEBITDAGoalGoalNumberEleven
175000000
CY2021Q1 axon Revenue Goal Goal Number Four
RevenueGoalGoalNumberFour
1210058000
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Twelve
AdjustedEBITDAGoalGoalNumberTwelve
190000000
CY2021Q1 axon Revenue Goal Goal Number Five
RevenueGoalGoalNumberFive
1410058000
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Thirteen
AdjustedEBITDAGoalGoalNumberThirteen
200000000
CY2021Q1 axon Revenue Goal Goal Number Six
RevenueGoalGoalNumberSix
1610058000
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Fourteen
AdjustedEBITDAGoalGoalNumberFourteen
210000000
CY2021Q1 axon Revenue Goal Goal Number Seven
RevenueGoalGoalNumberSeven
1810058000
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Fifteen
AdjustedEBITDAGoalGoalNumberFifteen
220000000
CY2021Q1 axon Revenue Goal Goal Number Eight
RevenueGoalGoalNumberEight
2010058000
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Sixteen
AdjustedEBITDAGoalGoalNumberSixteen
230000000
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Ten
AdjustedEBITDAGoalGoalNumberTen
155000000.0
CY2021Q1 axon Revenue Goal Goal Number One
RevenueGoalGoalNumberOne
710100000
CY2021Q1 axon Revenue Goal Goal Number Two
RevenueGoalGoalNumberTwo
860100000
CY2021Q1 axon Revenue Goal Goal Number Three
RevenueGoalGoalNumberThree
1010100000
CY2021Q1 axon Revenue Goal Goal Number Four
RevenueGoalGoalNumberFour
1210100000
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Eleven
AdjustedEBITDAGoalGoalNumberEleven
175000000.0
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Twelve
AdjustedEBITDAGoalGoalNumberTwelve
190000000.0
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Thirteen
AdjustedEBITDAGoalGoalNumberThirteen
200000000.0
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Fourteen
AdjustedEBITDAGoalGoalNumberFourteen
210000000.0
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Fourteen
AdjustedEBITDAGoalGoalNumberFourteen
210000000.0
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Fifteen
AdjustedEBITDAGoalGoalNumberFifteen
220000000.0
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Sixteen
AdjustedEBITDAGoalGoalNumberSixteen
230000000.0
CY2021Q1 axon Adjusted Ebitda Goal Goal Number Nine
AdjustedEBITDAGoalGoalNumberNine
125000000.0
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
132400000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
89610000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
20195000
CY2021Q1 axon Maximum Ratio Of Liabilities To Tangible Net Worth
MaximumRatioOfLiabilitiesToTangibleNetWorth
2.50
CY2021Q1 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
5
CY2021Q1 us-gaap Self Insurance Reserve
SelfInsuranceReserve
5000000.0
CY2021Q1 axon Employee Deferrals Vested Percentage
EmployeeDeferralsVestedPercentage
1
CY2021Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
2100000
CY2020Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1500000
CY2021Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
195019000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
147162000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
71666000
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
58554000
CY2021Q1 us-gaap Gross Profit
GrossProfit
123353000
CY2020Q1 us-gaap Gross Profit
GrossProfit
88608000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47018000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26381000

Files In Submission

Name View Source Status
0001558370-21-006312-index-headers.html Edgar Link pending
0001558370-21-006312-index.html Edgar Link pending
0001558370-21-006312.txt Edgar Link pending
0001558370-21-006312-xbrl.zip Edgar Link pending
axon-20210331.xsd Edgar Link pending
axon-20210331x10q.htm Edgar Link pending
axon-20210331x10q_htm.xml Edgar Link completed
axon-20210331xex31d1.htm Edgar Link pending
axon-20210331xex31d2.htm Edgar Link pending
axon-20210331xex32.htm Edgar Link pending
axon-20210331_cal.xml Edgar Link unprocessable
axon-20210331_def.xml Edgar Link unprocessable
axon-20210331_lab.xml Edgar Link unprocessable
axon-20210331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending